Sugi Predict

Sugi Predict / Compounds / SCHEMBL3614973

SCHEMBL3614973

SCHEMBL3614973

O=C(O)/C=C/c1cccc(Br)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ HDAC3 O15379 3/20 0.46
▸ HDAC4 P56524 3/20 0.46
▸ HDAC1 Q13547 3/20 0.46
▸ HDAC7 Q8WUI4 3/20 0.46
▸ HDAC2 Q92769 3/20 0.46
▸ HDAC10 Q969S8 3/20 0.46
▸ HDAC11 Q96DB2 3/20 0.46
▸ HDAC8 Q9BY41 3/20 0.46
▸ HDAC6 Q9UBN7 3/20 0.46
▸ HDAC9 Q9UKV0 3/20 0.46
▸ HDAC5 Q9UQL6 3/20 0.46
▸ HCAR2 Q8TDS4 4/20 0.44
▸ TNKS O95271 1/20 0.44
▸ TNKS2 Q9H2K2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.40
▸ STAT3 P40763 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614976 1.00 KDM4E (0.53) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL1580113 0.79 KDM4E (0.54) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL1580114 0.79 KDM4E (0.54) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL9757025 0.78 KDM4E (0.53) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL22165730 0.78 GRM4 (0.58) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL9756857 0.78 KDM4E (0.53) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL22776708 0.78 KDM4E (0.53) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL22776706 0.78 KDM4E (0.53) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL5756784 0.78 KDM4E (0.58) KDM4ELMNAHDAC3HDAC4HDAC1
SCHEMBL5756780 0.78 KDM4E (0.58) KDM4ELMNAHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210283139-A1 BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 AMPHISTA THERAPEUTICS LIMITED (GB) 2021-09-16 — — US disclosed
US-20210283139-A1 BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 AMPHISTA THERAPEUTICS LIMITED (GB) 2021-09-16 — — US disclosed
EP-3807263-A1 BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 Amphista Therapeutics Ltd (GB) 2021-04-21 — — EP disclosed
CN-112585127-A Bifunctional molecules for targeting Uchl5 安菲斯塔治疗有限责任公司 2021-03-30 — — CN disclosed
WO-2019238886-A1 BIFUNCTIONAL MOLECULES FOR TARGETING USP14 UNIVERSITY OF DUNDEE (GB) 2019-12-19 — — WO disclosed
WO-2019238886-A1 BIFUNCTIONAL MOLECULES FOR TARGETING USP14 UNIVERSITY OF DUNDEE (GB) 2019-12-19 — — WO disclosed
WO-2019238816-A1 BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 UNIVERSITY OF DUNDEE (GB) 2019-12-19 — — WO disclosed
WO-2019238816-A1 BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 UNIVERSITY OF DUNDEE (GB) 2019-12-19 — — WO disclosed
US-10005741-B2 Therapeutic compounds ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-06-26 — — US disclosed
US-20180141921-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-05-24 — — US disclosed
US-9181185-B2 Heteroaryl compounds as sodium channel blockers PURDUE PHARMA L.P. (US) 2015-11-10 — — US disclosed
US-20150291563-A1 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME YUHAN CORPORATION (KR) 2015-10-15 — — US disclosed
WO-2015130973-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2015-09-03 — — WO disclosed
US-20140288092-A1 HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. (US) 2014-09-25 — — US disclosed
WO-2013064883-A1 HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. (US) 2013-05-10 — — WO disclosed
US-8304438-B2 Heteroarylacrylamides and their use as pharmaceuticals SANOFI (FR) 2012-11-06 — — US disclosed
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 — — US disclosed
EP-2099753-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-16 — — EP disclosed
EP-1939180-A1 Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase sanofi-aventis (FR) 2008-07-02 — — EP disclosed
WO-2008074413-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE SANOFI-AVENTIS (FR) 2008-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288092-A1 HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS SCN1B, SCN2B, SCN1A KDM4E 2357/4885LMNA 1412/4885HDAC3 792/4885
US-20210283139-A1 BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 UCHL5, UCHL3, UCHL1 KDM4E 1032/4885LMNA 3714/4885HDAC3 2857/4885
US-20150291563-A1 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME NR1H3, NR1H2, NR1H4 KDM4E 2018/4885LMNA 4200/4885HDAC3 86/4885
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS NOS3, PTGIS, NOS1 KDM4E 1785/4885LMNA 2492/4885HDAC3 2103/4885
US-20180141921-A1 THERAPEUTIC COMPOUNDS IAPP, PARK7, NLN KDM4E 3451/4885LMNA 4506/4885HDAC3 1885/4885
US-10005741-B2 Therapeutic compounds IAPP, PARK7, NLN KDM4E 3451/4885LMNA 4506/4885HDAC3 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.